CHARLES SCHWAB INVESTMENT MANAGEMENT INC - ATEA PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of ATEA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,746,699
-18.6%
582,233
+1.4%
0.00%0.0%
Q2 2023$2,146,607
+21.7%
573,959
+9.0%
0.00%0.0%
Q1 2023$1,763,269
-35.1%
526,349
-6.8%
0.00%0.0%
Q4 2022$2,715,216
-13.8%
564,494
+2.0%
0.00%0.0%
Q3 2022$3,149,000
+3.7%
553,324
+29.4%
0.00%0.0%
Q2 2022$3,037,000
+1.4%
427,721
+3.2%
0.00%0.0%
Q1 2022$2,994,000
-15.3%
414,597
+4.9%
0.00%0.0%
Q4 2021$3,534,000
-74.4%
395,247
+0.5%
0.00%
-80.0%
Q3 2021$13,785,000
+226.8%
393,179
+100.3%
0.01%
+400.0%
Q2 2021$4,218,000
-23.1%
196,339
+121.0%
0.00%
-50.0%
Q1 2021$5,486,000
+51.9%
88,840
+2.8%
0.00%
+100.0%
Q4 2020$3,612,00086,4340.00%
Other shareholders
ATEA PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Tyrus Capital S.A.M. 1,260,000$3,780,00035.90%
BML Capital Management, LLC 4,800,000$14,400,00013.22%
Stonepine Capital Management, LLC 1,720,000$5,160,0001.71%
TANG CAPITAL MANAGEMENT LLC 3,600,000$10,800,0001.52%
CM Management, LLC 275,000$825,0000.88%
Bain Capital Life Sciences Investors, LLC 2,485,638$7,456,9140.83%
EcoR1 Capital, LLC 6,995,861$20,987,5830.71%
SECTORAL ASSET MANAGEMENT INC 600,461$1,801,3830.35%
Newtyn Management, LLC 400,000$1,200,0000.30%
Diametric Capital, LP 200,000$600,0000.25%
View complete list of ATEA PHARMACEUTICALS INC shareholders